Abstract:Midkine (MK) is a heparin-binding growth factor that functions in multiple physiological processes, making it a promising drug target for treating various diseases including osteoarthritis (OA). However, the lack of pharmacokinetic studies on MK limits further clinical research. As the N-domain of MK protein appears to be more important for its stability, this study aimed to investigate the pharmacokinetic profiles of recombinant human (rh)MK with different structures at the N-terminus via different administration routes in rats and guinea pigs. A single intramuscular (IM) injection of 1 mg/kg rhMK with or without extended sequences at the N-terminus expressed by E. coli or Pichia was administered to six male SD rats. rhMK concentrations in sequential tail blood samples were measured by ELISA. rhMK without extended N-terminal sequences expressed by Pichia had a greater area under the curve (AUC), slower clearance, and longer half-life in rats following a single IM injection than those of the other rhMK proteins. The AUC values for rhMK after IM and intra-articular (IA) administration were 1523.3 ± 35.2 h × ng/mL and 872.0 ± 36.1 h × ng/mL, whereas the apparent volumes of distribution (Vd/f) were 0.184 ± 0.067 L/kg and 11.6 ± 0.8 L/kg, respectively, suggesting that rhMK was distributed more locally after IA injection than after IM injection as Vd/f magnitude gives a general idea of extent distribution in the body and higher Vd/f represents more locally distribution. rhMK concentration in the articular cartilage was markedly higher than that in serum and reached the highest level at 3 days after a single IA injection in Hartley guinea pigs. As the dose increased from 10 to 50 mg/kg, the AUC increased in a greater-than-dose-proportional manner, suggesting that rhMK exhibits non-linear pharmacokinetics in rats after a single IM injection in this dose range. These results indicated that the N-terminal structure and administration route have substantial effects on the pharmacokinetics of rhMK in rats. Furthermore, rhMK was maintained in articular cartilage with minimal diffusion into the blood following IA injection in Hartley guinea pigs, providing a foundation for clinical research on the use of rhMK for OA treatment via IA delivery.

Prokaryotic Expression, Refolding and Purification of High-Purity Mouse Midkine in Escherichia Coli

Eukaryotic Expression and Purification of Native Form of Mouse Midkine from Pichia Pastoris

Expression and Purification of Bioactive High-Purity Human Midkine in Escherichia Coli.

[Cloning and Efficient Expression of Cytokine Human MK in E. Coli].

Preparation and preliminary characterization of rabbit monoclonal antibodies against human midkine

[Expression of Midkine Fusion Protein and Preparation and Application of Its Monoclonal Antibodies].

Expression and purification of bioactive high-purity mouse monokine induced by IFN-γ in Escherichia coli

Cloning and Expression of Midkine Cytokine from Carcinogenesis Tissue in E.coli

The Site-Directed Mutagenesis and Prokaryotic Expression of Midkine Gene in Cynoglossus Semilaevis

Expression and Purification of Bioactive High-Purity Recombinant Mouse CXCL14 in Escherichia coli

Expression and Purification of the Fusion Protein of Mouse Macrophage Inflammatory Protein 1beta and Ret

Pharmacokinetics of midkine with different N-terminal structures in rats.

Novel modification of growth medium enables efficient E. coli expression and simple purification of an endotoxin-free recombinant murine hsp70 protein

Expression and Purification of Bioactive High-Purity Recombinant Mouse SPP1 in Escherichia coli

High-level expression and purification of human creatine kinase MM isozymes in E.coli

Production And Characterization Of, Bacterial Single - Chain Fv Fragment Specific To Human Midkine

Prokaryotic expression and purification of the Mus musculus Rig-Ⅰ protein and preparation of antibody

Purification and Refolding Escherichia Coli Produced Enterokinase Inclusion Bodies Immobilized by Nickel Chelating Chromatography

Purification and Renaturation of E.coli-Derived Mouse Granulocyte-Macrophage Colony Stimulating Factor

Efficient in Vitro Refolding and Characterization of Major Histocompatibility Complex Class I-Related Chain Molecules A (MICA) and Natural Killer Group 2 Member D (NKG2D) Expressed in E. Coli

Expression and Purification of Recombinant Human Mig in Escherichia Coli and Its Comparison with Murine Mig.